AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$RGNX

REGENXBIO Inc.

Price · $RGNXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $RGNX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $RGNX in the last 30 days.

Top stories · $RGNXMore →
APR 29·openPR.comMed

Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO

A new report by DelveInsight titled "Duchenne Muscular Dystrophy Pipeline Insight, 2026" details the active development of over 75 Duchenne Muscular Dystrophy (DMD) treatment therapies by more than 75 companies globally. The report provides a comprehensive analysis of the clinical trial landscape, therapy innovations, and FDA updates related to Duchenne Muscular Dystrophy. Recent developments highlighted include progress in clinical trials by companies like Precision BioSciences, Solid Biosciences, and REGENXBIO, as well as regulatory milestones such as Orphan Drug Designation and Breakthrough Therapy designation for new DMD treatments.

MAR 31·GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX), alleging that the company made materially false and misleading statements regarding its gene therapy RGX‑111 for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the lawsuit to recover damages by April 14, 2026. The firm operates on a contingency fee basis, seeking reimbursement only if successful.

MAR 26·Stock Titan

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

SUEWALLST, LLP has issued a notice alerting institutional investors holding REGENXBIO (RGNX) shares between February 9, 2022, and January 27, 2026, about potential portfolio losses due to alleged gene therapy fraud. The firm suggests these investors evaluate lead plaintiff opportunities in a pending securities class action. The lawsuit claims REGENXBIO made misleading statements regarding the safety of its RGX-111 gene therapy, leading to a 17.8% stock decline after an FDA clinical hold related to CNS tumor discovery.

News on $RGNX

All news →